Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial

Josep Tabernero, Eric Van Cutsem, Radek Lakomy, Jana Prausova, Paul Ruff, Guy A Van Hazel, Vladimir M Moiseyenko, David R Ferry, Joseph McKendrick, Karen Soussan-Lazard, Soazig Chevalier, Carmen J Allegra

Research output: Contribution to journalArticleResearchpeer-review

146 Citations (Scopus)

Abstract

The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen. In the present analysis, outcomes were evaluated in prespecified subgroups to assess the consistency of the treatment effect.
Original languageEnglish
Pages (from-to)320 - 331
Number of pages12
JournalEuropean Journal of Cancer
Volume50
Issue number2
DOIs
Publication statusPublished - 2014

Cite this